
1. Technology overview
Rozetta Co., Ltd. is a Tokyo company founded in February 2004, part of the Metareal Group, working on machine translation and AI language tools. RakuyakuAI applies generative AI to pharmaceutical documents, where review reports, regulatory files and internal SOPs are long and must stay consistent.
RakuyakuAI is a generative AI SaaS delivered in a dedicated environment for each client. Its lineup includes a medical writing editor for clinical study reports, a QC checker that detects numeric mismatches across documents, a Q&A assistant that cites its sources, and translation. More than ten pharmaceutical companies are reported as users.
2. Highlighted features & specifications
- MW Editor: Drafting support for clinical study reports with extension to protocols and CTD.
- QC Checker: Detects numeric mismatches within and across documents and shows supporting passages.
- Q&A Assistant: Answers questions over internal data and cites reference passages.
- Translation: T-4OO translation for pharmaceutical documents.
- Custom development: CDP program for client-specific extensions.
- Dedicated environment: Separate secure environment for each client.
3. Potential application
A Vietnamese drug manufacturer could cross-check numbers between registration dossiers and batch records. A CRO could speed up drafting of clinical study report sections.
4. Benefits
Document QC detects numeric inconsistencies across multiple documents automatically. Answers cite the source passages, which supports transparency for reviewers. A dedicated environment per client allows confidential information to be used safely. Pharma companies report adoption by more than ten firms.
5. Market trends & opportunities
Pharmaceutical firms are adopting generative AI to cut documentation workload in regulatory submission and quality work. Vietnamese and ASEAN drug makers and CROs preparing multi-country filings face similar document volume.
6. Other information
Rozetta was founded in February 2004 and has its headquarters in Chiyoda-ku, Tokyo per the press release. The site lists the tool as eligible for a 2026 digital and AI adoption subsidy covering 50 percent of cost. A joint study with a national cancer center is listed.
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE








































